109 related articles for article (PubMed ID: 34418874)
1. Systematic transition modeling analysis in the MEF2B-DNA binding interface due to Y69H and K4E variants.
Zia A; Rashid S
J Mol Graph Model; 2021 Nov; 108():108009. PubMed ID: 34418874
[TBL] [Abstract][Full Text] [Related]
2. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.
Pon JR; Wong J; Saberi S; Alder O; Moksa M; Grace Cheng SW; Morin GB; Hoodless PA; Hirst M; Marra MA
Nat Commun; 2015 Aug; 6():7953. PubMed ID: 26245647
[TBL] [Abstract][Full Text] [Related]
3. In Silico Exploration of Conformational Dynamics and Novel Inhibitors for Targeting MEF2-Associated Transcriptional Activity.
Zia A; Imran M; Rashid S
J Chem Inf Model; 2020 Mar; 60(3):1892-1909. PubMed ID: 32031799
[TBL] [Abstract][Full Text] [Related]
4. MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.
Brescia P; Schneider C; Holmes AB; Shen Q; Hussein S; Pasqualucci L; Basso K; Dalla-Favera R
Cancer Cell; 2018 Sep; 34(3):453-465.e9. PubMed ID: 30205047
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
6. Crystal Structure of Apo MEF2B Reveals New Insights in DNA Binding and Cofactor Interaction.
Lei X; Shi H; Kou Y; Rajashekar N; Wu F; Sen C; Xu J; Chen L
Biochemistry; 2018 Jul; 57(28):4047-4051. PubMed ID: 29944822
[TBL] [Abstract][Full Text] [Related]
7. Landscape of DNA binding signatures of myocyte enhancer factor-2B reveals a unique interplay of base and shape readout.
Dantas Machado AC; Cooper BH; Lei X; Di Felice R; Chen L; Rohs R
Nucleic Acids Res; 2020 Sep; 48(15):8529-8544. PubMed ID: 32738045
[TBL] [Abstract][Full Text] [Related]
8. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
[TBL] [Abstract][Full Text] [Related]
9. MEF2B is a potent transactivator expressed in early myogenic lineages.
Molkentin JD; Firulli AB; Black BL; Martin JF; Hustad CM; Copeland N; Jenkins N; Lyons G; Olson EN
Mol Cell Biol; 1996 Jul; 16(7):3814-24. PubMed ID: 8668199
[TBL] [Abstract][Full Text] [Related]
10. Structure of the MADS-box/MEF2 domain of MEF2A bound to DNA and its implication for myocardin recruitment.
Wu Y; Dey R; Han A; Jayathilaka N; Philips M; Ye J; Chen L
J Mol Biol; 2010 Mar; 397(2):520-33. PubMed ID: 20132824
[TBL] [Abstract][Full Text] [Related]
11. The Cancer Mutation D83V Induces an α-Helix to β-Strand Conformation Switch in MEF2B.
Lei X; Kou Y; Fu Y; Rajashekar N; Shi H; Wu F; Xu J; Luo Y; Chen L
J Mol Biol; 2018 Apr; 430(8):1157-1172. PubMed ID: 29477338
[TBL] [Abstract][Full Text] [Related]
12. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
13. [Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance].
Liu F; Liu Q; Guo N; Zhang GM; Deng YF; Hu WW; Rao HL
Zhonghua Bing Li Xue Za Zhi; 2020 Jan; 49(1):40-46. PubMed ID: 31914533
[No Abstract] [Full Text] [Related]
14. Mouse Mef2b gene: unique member of MEF2 gene family.
Morisaki T; Sermsuvitayawong K; Byun SH; Matsuda Y; Hidaka K; Morisaki H; Mukai T
J Biochem; 1997 Nov; 122(5):939-46. PubMed ID: 9443808
[TBL] [Abstract][Full Text] [Related]
15. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas.
Krenács D; Borbényi Z; Bedekovics J; Méhes G; Bagdi E; Krenács L
Virchows Arch; 2015 Sep; 467(3):345-55. PubMed ID: 26089142
[TBL] [Abstract][Full Text] [Related]
16. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2.
Han A; Pan F; Stroud JC; Youn HD; Liu JO; Chen L
Nature; 2003 Apr; 422(6933):730-4. PubMed ID: 12700764
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2.
Han A; He J; Wu Y; Liu JO; Chen L
J Mol Biol; 2005 Jan; 345(1):91-102. PubMed ID: 15567413
[TBL] [Abstract][Full Text] [Related]
19. DNA damage induced apoptosis suppressor (DDIAS) is upregulated via ERK5/MEF2B signaling and promotes β-catenin-mediated invasion.
Im JY; Yoon SH; Kim BK; Ban HS; Won KJ; Chung KS; Jung KE; Won M
Biochim Biophys Acta; 2016 Nov; 1859(11):1449-1458. PubMed ID: 27412911
[TBL] [Abstract][Full Text] [Related]
20. The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.
Magistri M; Happ LE; Ramdial J; Lu X; Stathias V; Kunkalla K; Agarwal N; Jiang X; Schürer SC; Dubovy SR; Chapman JR; Vega F; Dave S; Lossos IS
Cancer Res Commun; 2021 Oct; 1(1):1-16. PubMed ID: 35528192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
